Skip to main content
Erschienen in: Tumor Biology 12/2016

06.10.2016 | Original Article

miR-203 is a predictive biomarker for colorectal cancer and its expression is associated with BIRC5

verfasst von: Qiang Fu, Jun Zhang, Xin Xu, Fei Qian, Ke Feng, Jie Ma

Erschienen in: Tumor Biology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to explore the role of miR-203 in colorectal cancer (CRC) and evaluate the correlation between miR-203 and BIRC5. The expressions of miR-203 in the tissues of 122 CRC patients (with non-tumor tissues as controls) and those from 30 healthy donors were detected by TaqMan® MicroRNA assay. BIRC5s expressions in CRC and non-tumor tissues were detected by immunohistochemistry. Significantly less miR-203 was expressed in CRC tissues (P < 0.05) than in non-tumor tissues. Furthermore, low expression level of miR-203 was correlated with distant metastasis (DM), lymph node metastasis (LNM), and TNM stage (P < 0.05), but there were no significant differences between tumor size or gender. The positive expression rates of BIRC5 in CRC and non-tumor tissues were 73.77 % (90/122) and 30.32 % (37/122), respectively. The expression intensity of BIRC5 in CRC was significantly higher than that of non-tumor tissues (P < 0.05). It was significantly correlated with DM, LNM, and TNM stage (P < 0.05). Finally, miR-203 expression was negatively associated with that of BIRC5 (r = −0.8150, P < 0.05). In conclusion, miR-203 was down-regulated in CRC tissues and involved in the onset and progression of CRC. The expressions of miR-203 and BIRC5 in CRC were significantly negatively correlated, suggesting that BIRC5 may be regulated by miR-203. miR-203 is a potential suppressor and predictive biomarker for CRC.
Literatur
1.
Zurück zum Zitat Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2014;64(2):104–17.CrossRefPubMed Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2014;64(2):104–17.CrossRefPubMed
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
3.
Zurück zum Zitat Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, Yu H, et al. Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 2014;6(4):391–401.PubMedPubMedCentral Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, Yu H, et al. Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 2014;6(4):391–401.PubMedPubMedCentral
4.
Zurück zum Zitat AG X, ZJ Y, Jiang B, Wang XY, Zhong XH, Liu JH, Lou QY, Gan AH. Coloerectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol. 2010;16:906–65. AG X, ZJ Y, Jiang B, Wang XY, Zhong XH, Liu JH, Lou QY, Gan AH. Coloerectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol. 2010;16:906–65.
5.
Zurück zum Zitat Weitz J, Koch M, Debus J, Hohler T, Galle PR, et al. Colorectal cancer. Lancet. 2005;365:153–65.CrossRefPubMed Weitz J, Koch M, Debus J, Hohler T, Galle PR, et al. Colorectal cancer. Lancet. 2005;365:153–65.CrossRefPubMed
6.
Zurück zum Zitat Kozomara A, Griffths-Jones S. miRBase: annotationg high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:68–73.CrossRef Kozomara A, Griffths-Jones S. miRBase: annotationg high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:68–73.CrossRef
7.
Zurück zum Zitat Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adeno carcinoma[J. Mol Diagn. 2010;12:433–40.CrossRef Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adeno carcinoma[J. Mol Diagn. 2010;12:433–40.CrossRef
8.
Zurück zum Zitat Chen DL, Wang ZQ, Zl Z. Identificantion of miR 214 as a negative regulator of colorectal cancer liver metastasis via regulation of FGFR 1 expression. Hepatology. 2014;60(2):598–609.CrossRefPubMed Chen DL, Wang ZQ, Zl Z. Identificantion of miR 214 as a negative regulator of colorectal cancer liver metastasis via regulation of FGFR 1 expression. Hepatology. 2014;60(2):598–609.CrossRefPubMed
9.
Zurück zum Zitat Zhang H, Li W, Nan F, Wang H, Xu Y, et al. MicroRNA expression profile of colon cancer stem-like cells in HT 29 adenocarcinoma cell line. Biochem Biophys Res Commun. 2011;404:273–8.CrossRefPubMed Zhang H, Li W, Nan F, Wang H, Xu Y, et al. MicroRNA expression profile of colon cancer stem-like cells in HT 29 adenocarcinoma cell line. Biochem Biophys Res Commun. 2011;404:273–8.CrossRefPubMed
11.
Zurück zum Zitat Pavlyukov MS, Antipova NV, Balashova MV, et al. Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem. 2011;286:23296–307.CrossRefPubMedPubMedCentral Pavlyukov MS, Antipova NV, Balashova MV, et al. Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem. 2011;286:23296–307.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Lamers F, Schild L, Koser J, et al. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer. 2012;5:763–71.CrossRef Lamers F, Schild L, Koser J, et al. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer. 2012;5:763–71.CrossRef
13.
Zurück zum Zitat Tao H-Q, He X-J, Ma Y-Y, et al. Evaluation of REG4 for early diagnosis and prognosis of gastric cancer. Hum Pathol. 2011;42:1401–9.CrossRefPubMed Tao H-Q, He X-J, Ma Y-Y, et al. Evaluation of REG4 for early diagnosis and prognosis of gastric cancer. Hum Pathol. 2011;42:1401–9.CrossRefPubMed
14.
Zurück zum Zitat Hussain MU. Micro-RNAs (miRNAs): genomic organization, biogenesis and mode of action. Cell Tissue Res. 2012;349(2):405–13.CrossRef Hussain MU. Micro-RNAs (miRNAs): genomic organization, biogenesis and mode of action. Cell Tissue Res. 2012;349(2):405–13.CrossRef
15.
Zurück zum Zitat Smith CM, Watson DI, Michael MZ, Hussey DJ. MicroRNAs development of Barrett’s esophagus, and progression to esophageal adenocarcinoma. World J of Gastroenterology 2010;6:531–537. Smith CM, Watson DI, Michael MZ, Hussey DJ. MicroRNAs development of Barrett’s esophagus, and progression to esophageal adenocarcinoma. World J of Gastroenterology 2010;6:531–537.
16.
Zurück zum Zitat Furuta M, Kozaki K-i, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31(5):766–76.CrossRefPubMed Furuta M, Kozaki K-i, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31(5):766–76.CrossRefPubMed
17.
Zurück zum Zitat Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, et al. miR-203 controls proliferation, migration, and invasive potential of prostate cancer cell lines. Cell Cycle. 2011;10(7):1121–31.CrossRefPubMed Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, et al. miR-203 controls proliferation, migration, and invasive potential of prostate cancer cell lines. Cell Cycle. 2011;10(7):1121–31.CrossRefPubMed
18.
Zurück zum Zitat Zhang Z, Zhang B, Li W, Fu L, Fu L, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer. 2011;2(8):782–91.CrossRefPubMedPubMedCentral Zhang Z, Zhang B, Li W, Fu L, Fu L, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer. 2011;2(8):782–91.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Wang W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z. miR-203 inhibits proliferation of HCC cells by targeting Survivn. Cell Biochem Funct. 2013;31:82–5.CrossRef Wang W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z. miR-203 inhibits proliferation of HCC cells by targeting Survivn. Cell Biochem Funct. 2013;31:82–5.CrossRef
20.
Zurück zum Zitat Chiang Y, Song Y, Wang Z, Chen Y, Yue Z, Xu H, Xing C, Liu Z. Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J Gastrointest Surg. 2011;15(1):63–70.CrossRefPubMed Chiang Y, Song Y, Wang Z, Chen Y, Yue Z, Xu H, Xing C, Liu Z. Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J Gastrointest Surg. 2011;15(1):63–70.CrossRefPubMed
21.
Zurück zum Zitat Zheng Jiang C, Li Hua H, ShaoJun H. Polymorphism of survivin promoter regions—31 g/C and gastric cancer. Cancer. 2008;27(3):258–63. Zheng Jiang C, Li Hua H, ShaoJun H. Polymorphism of survivin promoter regions—31 g/C and gastric cancer. Cancer. 2008;27(3):258–63.
22.
Zurück zum Zitat Ulukus EC, Kargi HA, Sis B, Lebe B, Oztop I, et al. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Applied Immunohistochemistry &Molecular Morphology. 2007;15:31–7.CrossRef Ulukus EC, Kargi HA, Sis B, Lebe B, Oztop I, et al. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Applied Immunohistochemistry &Molecular Morphology. 2007;15:31–7.CrossRef
23.
Zurück zum Zitat Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007;70:482–6.CrossRefPubMed Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007;70:482–6.CrossRefPubMed
24.
Zurück zum Zitat Li QX, CongYa Y, XiaoLu Y, et al. FGFR1 and survivin expression analysis of clinical significance in breast infiltrating ductal carcinoma tissue. Chinese Journal of Cancer Prevention and Treatment. 2013;20(17):1315–22. Li QX, CongYa Y, XiaoLu Y, et al. FGFR1 and survivin expression analysis of clinical significance in breast infiltrating ductal carcinoma tissue. Chinese Journal of Cancer Prevention and Treatment. 2013;20(17):1315–22.
25.
Zurück zum Zitat Yan Z, QiChang Y, HongBing L, et al. The expression of osteopontin, survivin and BCL—2 and clinical significance of cervical lesions. Cancer Research on Prevention and Treatment. 2013;4(1):83–6. Yan Z, QiChang Y, HongBing L, et al. The expression of osteopontin, survivin and BCL—2 and clinical significance of cervical lesions. Cancer Research on Prevention and Treatment. 2013;4(1):83–6.
26.
Zurück zum Zitat Zhou XL, Lin CC. Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer; a systematic review and meta-analysis. World J Surg Oncol. 2015;13:27.CrossRefPubMedPubMedCentral Zhou XL, Lin CC. Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer; a systematic review and meta-analysis. World J Surg Oncol. 2015;13:27.CrossRefPubMedPubMedCentral
Metadaten
Titel
miR-203 is a predictive biomarker for colorectal cancer and its expression is associated with BIRC5
verfasst von
Qiang Fu
Jun Zhang
Xin Xu
Fei Qian
Ke Feng
Jie Ma
Publikationsdatum
06.10.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5438-7

Weitere Artikel der Ausgabe 12/2016

Tumor Biology 12/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.